Re: What's the deal with Zenith?
in response to
by
posted on
Jun 24, 2023 12:56PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Toinv & tada ... I am not overcome with optimism & hope right now, nor delusional about the challeneges with the process or outcome. I am just glad that there is a "plan" and some creativity for progress, of some kind. Always maintain motion & initiative, rather than just sitting in the dark listening to country music swilling on Jack Daniels (not that anything is wrong with that at times), and hoping something changes.
And this actually seems "possible," with potential benefits for all, with/for the right BP ... characteristics of which have already been identified. I would give this a 30-40% chance off the cuff, which is better than just sitting on his thumb. And when talks are ongoing, there are many twists & turns that can take place.
To me, anything that potentially links both Zenith and RVX together with a BP, is a good thing, and advancement.
Whether this specific concept comes to fruition, or a different one eventually comes to fruition, just keep it moving .... and keep RVX visible in discussions.
And I don't think he would be throwing things like this out there, unless he has already had some degree of "concept" talks jmho.